Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Inv. presentation
Appointed director
Quarterly results
CC transcript

HUMAN GENOME SCIENCES INC (HGSI) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/21/2011 BW Human Genome Sciences Announces Second Quarter 2011 Financial Results and Key Developments
07/14/2011 BW Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2011 Financial Results
06/06/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference
05/20/2011 BW Human Genome Sciences to Host May 20 Conference Call to Discuss the Positive Opinion Received in Europe from the CHMP for BENLYSTA® (Belimumab)
05/20/2011 BW GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA® (Belimumab)
05/02/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
04/28/2011 BW Human Genome Sciences Announces First Quarter 2011 Financial Results and Key Developments
04/14/2011 BW Human Genome Sciences Updates Investors on Progress of BENLYSTA® Launch and Future Priorities
04/07/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentations at Analyst & Investor Meeting
03/16/2011 BW Human Genome Sciences and FivePrime Therapeutics Announce Development and Commercialization Agreement for Novel Anti-Cancer Drug
03/14/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Barclays Capital Conference
03/14/2011 BW Human Genome Sciences Appoints George Morrow to its Board of Directors
03/09/2011 BW Human Genome Sciences and GlaxoSmithKline Announce FDA Approval of BENLYSTA® (Belimumab) for Treatment of Systemic Lupus Erythematosus
03/03/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen and Company Conference
02/25/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at RBC Capital Conference
02/24/2011 BW Human Genome Sciences Announces Fourth-Quarter and Full-Year Financial Results and Key Developments
02/15/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Leerink Swann Conference
02/11/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor Conference
02/10/2011 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at ISI Annual Conference
12/14/2010 BW Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
12/03/2010 BW Human Genome Sciences and GlaxoSmithKline Announce FDA Extension of BENLYSTA® PDUFA Target Date to March 10, 2011
11/16/2010 BW Human Genome Sciences and GlaxoSmithKline Announce Vote of FDA Advisory Committee to Recommend Approval of BENLYSTA® for Systemic Lupus Erythematosus
10/27/2010 BW Human Genome Sciences Announces Third Quarter 2010 Financial Results and Key Developments
09/23/2010 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Healthcare Conference
09/16/2010 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Healthcare Conference
09/14/2010 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Stifel Nicolaus Healthcare Conference
09/09/2010 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Morgan Stanley Healthcare Conference
08/19/2010 BW Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA® (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
08/13/2010 BW Human Genome Sciences Names Tuomo Pätsi Vice President, HGS Europe
07/22/2010 BW Human Genome Sciences Announces Second Quarter 2010 Financial Results and Key Developments
07/13/2010 BW Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for BENLYSTA®, a Potential New Treatment for Systemic Lupus Erythematosus
07/13/2010 BW Human Genome Sciences and Lonza Enter Commercial Manufacturing Agreement for BENLYSTA®, a Potential New Treatment for Systemic Lupus Erythematosus
06/25/2010 BW Human Genome Sciences Announces Presentation of Additional Phase 3 SLE Study Results for BENLYSTA® (Belimumab) at International Congress on SLE
06/21/2010 BW Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at NASDAQ OMX 24th Investor Program
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy